Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo

Abstract Recently, we reported that 3 of the known risk factors of Alzheimer's disease (AD), i.e., advanced age, apolipoprotein E (ApoE) ε4, and female gender, are associated with differential levels of ApoE proteins and butyrylcholinesterase (BuChE) in the cerebrospinal fluid (CSF) of AD patie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurobiology of aging 2011-12, Vol.32 (12), p.2320.e15-2320.e32
Hauptverfasser: Darreh-Shori, Taher, Forsberg, Anton, Modiri, Negar, Andreasen, Niels, Blennow, Kaj, Kamil, Chelenk, Ahmed, Hiba, Almkvist, Ove, Långström, Bengt, Nordberg, Agneta
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2320.e32
container_issue 12
container_start_page 2320.e15
container_title Neurobiology of aging
container_volume 32
creator Darreh-Shori, Taher
Forsberg, Anton
Modiri, Negar
Andreasen, Niels
Blennow, Kaj
Kamil, Chelenk
Ahmed, Hiba
Almkvist, Ove
Långström, Bengt
Nordberg, Agneta
description Abstract Recently, we reported that 3 of the known risk factors of Alzheimer's disease (AD), i.e., advanced age, apolipoprotein E (ApoE) ε4, and female gender, are associated with differential levels of ApoE proteins and butyrylcholinesterase (BuChE) in the cerebrospinal fluid (CSF) of AD patients. The ApoE ε4 allele and certain BuChE polymorphisms synergistically affect the conversion rate of mild cognitive impairment (MCI) to AD. Here, we investigated interrelationships between ApoE and BuChE levels, and pathological markers of AD in vivo. CSF from patients with probable AD, assessed for cerebral glucose metabolism (CMRglc; n = 50) and Pittsburgh compound B (PIB) retention (β-amyloid [Aβ] load, n = 29) by positron emission tomography (PET), was used for measurement of BuChE, ApoE, Aβ, tau, phosphorylated tau (P-tau) and interleukin-1β (IL-1β) levels. Levels of ApoE and BuChE strongly correlated with CMRglc (fluorodeoxyglucose [FDG]-PET, r = 0.54, p < 0.0001, n = 50), cerebral Aβ load (PIB retention, r = 0.73, p < 0.0001, n = 29), and CSF P-tau ( r = 0.73, p < 0.0001, n = 33). High ApoE protein was tied to low CMRglc and high PIB retention and P-tau. BuChE levels had opposite relationships. Other CSF covariates were levels of interleukin-1β and Aβ42 peptide. The pattern of the patients' cognitive Z -scores strongly supported these observations. High ApoE protein was also linked to changes in 3 of the biodynamic properties of BuChE. In vitro analysis indicated that high ApoE protein levels were related to an increased pool of dormant BuChE molecules with an abnormally high intrinsic catalytic rate in CSF, which was “turned on” by excess Aβ peptides. The findings suggest that abnormally high levels of ApoE may play a causative role in the pathological events of AD, particularly those involving the early cholinergic deficit in the AD brain, through modulation of cholinesterases activities, hence disturbing the acetylcholine-dependent activity of neurons and nonexcitable cells such as glial cells.
doi_str_mv 10.1016/j.neurobiolaging.2010.04.028
format Article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_550841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0197458010002034</els_id><sourcerecordid>911157939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c653t-380148fded117b2ebbfddc00f0808f9ce77a930fb1f225bb930a20eed7291f693</originalsourceid><addsrcrecordid>eNqNk12L1DAUhoso7jj6FyQXwl5ox5P0IymIMOyHCgte-HEb0va0k9lOUpN2hvG_-F9Nd8YFBR0hkEPy5D0teRJFLygsKND89XphcHS21LZTrTbtgkHYgnQBTDyIZjTLREzTgj-MZkALHqeZgLPoifdrAOApzx9HZwyyRCQ8nUU_LnXToEMzaNWRDrfYeWIbonrb6d72zg6oDbkiytSkHIe923fVKuwZ9AM65ZH4ld0RPzhrWqK8t5VWg7aG7PSwIr0aAm1bXYV4r1tzl77svq9Qb9Cde1Jrj1NM6DKskJROhSqMrd7ap9GjRnUenx3nefTl-urzxfv45uO7DxfLm7jKs2SIEwE0FU2NNaW8ZFiWTV1XAA0IEE1RIeeqSKApacNYVpahVgwQa84K2uRFMo_iQ67fYT-Wsnd6o9xeWqXlcek2VCizDERK_8m3Yy_DUjtOPGW5oCLwr_7KX-qvS2ldK8dR0pyld_EvT-N-lBzSNAv0-YEOl_VtDNciN9pX2HXKoB29LCilGS-S4jQJLMk5z_KTpCgELSgEfh69OZCVs947bO6_loKchJVr-buwchJWQiqDsOH482OjsdxgfX_4l6EBuD4AQUzcanTSVxpNhbV2WA2ytvp_O739I6gKFk9e3uIe_dqOzgTHJJWeSZCfpsczvZ3wl8AgSZOf14gfkQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>898191002</pqid></control><display><type>article</type><title>Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Darreh-Shori, Taher ; Forsberg, Anton ; Modiri, Negar ; Andreasen, Niels ; Blennow, Kaj ; Kamil, Chelenk ; Ahmed, Hiba ; Almkvist, Ove ; Långström, Bengt ; Nordberg, Agneta</creator><creatorcontrib>Darreh-Shori, Taher ; Forsberg, Anton ; Modiri, Negar ; Andreasen, Niels ; Blennow, Kaj ; Kamil, Chelenk ; Ahmed, Hiba ; Almkvist, Ove ; Långström, Bengt ; Nordberg, Agneta</creatorcontrib><description>Abstract Recently, we reported that 3 of the known risk factors of Alzheimer's disease (AD), i.e., advanced age, apolipoprotein E (ApoE) ε4, and female gender, are associated with differential levels of ApoE proteins and butyrylcholinesterase (BuChE) in the cerebrospinal fluid (CSF) of AD patients. The ApoE ε4 allele and certain BuChE polymorphisms synergistically affect the conversion rate of mild cognitive impairment (MCI) to AD. Here, we investigated interrelationships between ApoE and BuChE levels, and pathological markers of AD in vivo. CSF from patients with probable AD, assessed for cerebral glucose metabolism (CMRglc; n = 50) and Pittsburgh compound B (PIB) retention (β-amyloid [Aβ] load, n = 29) by positron emission tomography (PET), was used for measurement of BuChE, ApoE, Aβ, tau, phosphorylated tau (P-tau) and interleukin-1β (IL-1β) levels. Levels of ApoE and BuChE strongly correlated with CMRglc (fluorodeoxyglucose [FDG]-PET, r = 0.54, p &lt; 0.0001, n = 50), cerebral Aβ load (PIB retention, r = 0.73, p &lt; 0.0001, n = 29), and CSF P-tau ( r = 0.73, p &lt; 0.0001, n = 33). High ApoE protein was tied to low CMRglc and high PIB retention and P-tau. BuChE levels had opposite relationships. Other CSF covariates were levels of interleukin-1β and Aβ42 peptide. The pattern of the patients' cognitive Z -scores strongly supported these observations. High ApoE protein was also linked to changes in 3 of the biodynamic properties of BuChE. In vitro analysis indicated that high ApoE protein levels were related to an increased pool of dormant BuChE molecules with an abnormally high intrinsic catalytic rate in CSF, which was “turned on” by excess Aβ peptides. The findings suggest that abnormally high levels of ApoE may play a causative role in the pathological events of AD, particularly those involving the early cholinergic deficit in the AD brain, through modulation of cholinesterases activities, hence disturbing the acetylcholine-dependent activity of neurons and nonexcitable cells such as glial cells.</description><identifier>ISSN: 0197-4580</identifier><identifier>ISSN: 1558-1497</identifier><identifier>EISSN: 1558-1497</identifier><identifier>DOI: 10.1016/j.neurobiolaging.2010.04.028</identifier><identifier>PMID: 20538374</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Alzheimer Disease - cerebrospinal fluid ; Alzheimer Disease - enzymology ; Alzheimer Disease - pathology ; Alzheimer’s disease ; apolipoprotein E ; Apolipoprotein E4 - blood ; Apolipoprotein E4 - cerebrospinal fluid ; Biomarkers - blood ; Biomarkers - cerebrospinal fluid ; brain ; Brain - enzymology ; Brain - pathology ; butyrylcholinesterase ; Butyrylcholinesterase - cerebrospinal fluid ; Female ; Humans ; Internal Medicine ; Male ; Middle Aged ; Neurology ; Psychiatry ; Psychology ; Psykiatri ; Psykologi ; Risk Factors ; SAMHÄLLSVETENSKAP ; SOCIAL SCIENCES ; Socialvetenskap</subject><ispartof>Neurobiology of aging, 2011-12, Vol.32 (12), p.2320.e15-2320.e32</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c653t-380148fded117b2ebbfddc00f0808f9ce77a930fb1f225bb930a20eed7291f693</citedby><cites>FETCH-LOGICAL-c653t-380148fded117b2ebbfddc00f0808f9ce77a930fb1f225bb930a20eed7291f693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0197458010002034$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20538374$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-70445$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-162441$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://gup.ub.gu.se/publication/126818$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:123531267$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Darreh-Shori, Taher</creatorcontrib><creatorcontrib>Forsberg, Anton</creatorcontrib><creatorcontrib>Modiri, Negar</creatorcontrib><creatorcontrib>Andreasen, Niels</creatorcontrib><creatorcontrib>Blennow, Kaj</creatorcontrib><creatorcontrib>Kamil, Chelenk</creatorcontrib><creatorcontrib>Ahmed, Hiba</creatorcontrib><creatorcontrib>Almkvist, Ove</creatorcontrib><creatorcontrib>Långström, Bengt</creatorcontrib><creatorcontrib>Nordberg, Agneta</creatorcontrib><title>Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo</title><title>Neurobiology of aging</title><addtitle>Neurobiol Aging</addtitle><description>Abstract Recently, we reported that 3 of the known risk factors of Alzheimer's disease (AD), i.e., advanced age, apolipoprotein E (ApoE) ε4, and female gender, are associated with differential levels of ApoE proteins and butyrylcholinesterase (BuChE) in the cerebrospinal fluid (CSF) of AD patients. The ApoE ε4 allele and certain BuChE polymorphisms synergistically affect the conversion rate of mild cognitive impairment (MCI) to AD. Here, we investigated interrelationships between ApoE and BuChE levels, and pathological markers of AD in vivo. CSF from patients with probable AD, assessed for cerebral glucose metabolism (CMRglc; n = 50) and Pittsburgh compound B (PIB) retention (β-amyloid [Aβ] load, n = 29) by positron emission tomography (PET), was used for measurement of BuChE, ApoE, Aβ, tau, phosphorylated tau (P-tau) and interleukin-1β (IL-1β) levels. Levels of ApoE and BuChE strongly correlated with CMRglc (fluorodeoxyglucose [FDG]-PET, r = 0.54, p &lt; 0.0001, n = 50), cerebral Aβ load (PIB retention, r = 0.73, p &lt; 0.0001, n = 29), and CSF P-tau ( r = 0.73, p &lt; 0.0001, n = 33). High ApoE protein was tied to low CMRglc and high PIB retention and P-tau. BuChE levels had opposite relationships. Other CSF covariates were levels of interleukin-1β and Aβ42 peptide. The pattern of the patients' cognitive Z -scores strongly supported these observations. High ApoE protein was also linked to changes in 3 of the biodynamic properties of BuChE. In vitro analysis indicated that high ApoE protein levels were related to an increased pool of dormant BuChE molecules with an abnormally high intrinsic catalytic rate in CSF, which was “turned on” by excess Aβ peptides. The findings suggest that abnormally high levels of ApoE may play a causative role in the pathological events of AD, particularly those involving the early cholinergic deficit in the AD brain, through modulation of cholinesterases activities, hence disturbing the acetylcholine-dependent activity of neurons and nonexcitable cells such as glial cells.</description><subject>Aged</subject><subject>Alzheimer Disease - cerebrospinal fluid</subject><subject>Alzheimer Disease - enzymology</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer’s disease</subject><subject>apolipoprotein E</subject><subject>Apolipoprotein E4 - blood</subject><subject>Apolipoprotein E4 - cerebrospinal fluid</subject><subject>Biomarkers - blood</subject><subject>Biomarkers - cerebrospinal fluid</subject><subject>brain</subject><subject>Brain - enzymology</subject><subject>Brain - pathology</subject><subject>butyrylcholinesterase</subject><subject>Butyrylcholinesterase - cerebrospinal fluid</subject><subject>Female</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Psychiatry</subject><subject>Psychology</subject><subject>Psykiatri</subject><subject>Psykologi</subject><subject>Risk Factors</subject><subject>SAMHÄLLSVETENSKAP</subject><subject>SOCIAL SCIENCES</subject><subject>Socialvetenskap</subject><issn>0197-4580</issn><issn>1558-1497</issn><issn>1558-1497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNk12L1DAUhoso7jj6FyQXwl5ox5P0IymIMOyHCgte-HEb0va0k9lOUpN2hvG_-F9Nd8YFBR0hkEPy5D0teRJFLygsKND89XphcHS21LZTrTbtgkHYgnQBTDyIZjTLREzTgj-MZkALHqeZgLPoifdrAOApzx9HZwyyRCQ8nUU_LnXToEMzaNWRDrfYeWIbonrb6d72zg6oDbkiytSkHIe923fVKuwZ9AM65ZH4ld0RPzhrWqK8t5VWg7aG7PSwIr0aAm1bXYV4r1tzl77svq9Qb9Cde1Jrj1NM6DKskJROhSqMrd7ap9GjRnUenx3nefTl-urzxfv45uO7DxfLm7jKs2SIEwE0FU2NNaW8ZFiWTV1XAA0IEE1RIeeqSKApacNYVpahVgwQa84K2uRFMo_iQ67fYT-Wsnd6o9xeWqXlcek2VCizDERK_8m3Yy_DUjtOPGW5oCLwr_7KX-qvS2ldK8dR0pyld_EvT-N-lBzSNAv0-YEOl_VtDNciN9pX2HXKoB29LCilGS-S4jQJLMk5z_KTpCgELSgEfh69OZCVs947bO6_loKchJVr-buwchJWQiqDsOH482OjsdxgfX_4l6EBuD4AQUzcanTSVxpNhbV2WA2ytvp_O739I6gKFk9e3uIe_dqOzgTHJJWeSZCfpsczvZ3wl8AgSZOf14gfkQ</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Darreh-Shori, Taher</creator><creator>Forsberg, Anton</creator><creator>Modiri, Negar</creator><creator>Andreasen, Niels</creator><creator>Blennow, Kaj</creator><creator>Kamil, Chelenk</creator><creator>Ahmed, Hiba</creator><creator>Almkvist, Ove</creator><creator>Långström, Bengt</creator><creator>Nordberg, Agneta</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DG7</scope><scope>DF2</scope><scope>F1U</scope></search><sort><creationdate>20111201</creationdate><title>Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo</title><author>Darreh-Shori, Taher ; Forsberg, Anton ; Modiri, Negar ; Andreasen, Niels ; Blennow, Kaj ; Kamil, Chelenk ; Ahmed, Hiba ; Almkvist, Ove ; Långström, Bengt ; Nordberg, Agneta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c653t-380148fded117b2ebbfddc00f0808f9ce77a930fb1f225bb930a20eed7291f693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Alzheimer Disease - cerebrospinal fluid</topic><topic>Alzheimer Disease - enzymology</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer’s disease</topic><topic>apolipoprotein E</topic><topic>Apolipoprotein E4 - blood</topic><topic>Apolipoprotein E4 - cerebrospinal fluid</topic><topic>Biomarkers - blood</topic><topic>Biomarkers - cerebrospinal fluid</topic><topic>brain</topic><topic>Brain - enzymology</topic><topic>Brain - pathology</topic><topic>butyrylcholinesterase</topic><topic>Butyrylcholinesterase - cerebrospinal fluid</topic><topic>Female</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Psychiatry</topic><topic>Psychology</topic><topic>Psykiatri</topic><topic>Psykologi</topic><topic>Risk Factors</topic><topic>SAMHÄLLSVETENSKAP</topic><topic>SOCIAL SCIENCES</topic><topic>Socialvetenskap</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Darreh-Shori, Taher</creatorcontrib><creatorcontrib>Forsberg, Anton</creatorcontrib><creatorcontrib>Modiri, Negar</creatorcontrib><creatorcontrib>Andreasen, Niels</creatorcontrib><creatorcontrib>Blennow, Kaj</creatorcontrib><creatorcontrib>Kamil, Chelenk</creatorcontrib><creatorcontrib>Ahmed, Hiba</creatorcontrib><creatorcontrib>Almkvist, Ove</creatorcontrib><creatorcontrib>Långström, Bengt</creatorcontrib><creatorcontrib>Nordberg, Agneta</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Stockholms universitet</collection><collection>SWEPUB Uppsala universitet</collection><collection>SWEPUB Göteborgs universitet</collection><jtitle>Neurobiology of aging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Darreh-Shori, Taher</au><au>Forsberg, Anton</au><au>Modiri, Negar</au><au>Andreasen, Niels</au><au>Blennow, Kaj</au><au>Kamil, Chelenk</au><au>Ahmed, Hiba</au><au>Almkvist, Ove</au><au>Långström, Bengt</au><au>Nordberg, Agneta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo</atitle><jtitle>Neurobiology of aging</jtitle><addtitle>Neurobiol Aging</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>32</volume><issue>12</issue><spage>2320.e15</spage><epage>2320.e32</epage><pages>2320.e15-2320.e32</pages><issn>0197-4580</issn><issn>1558-1497</issn><eissn>1558-1497</eissn><abstract>Abstract Recently, we reported that 3 of the known risk factors of Alzheimer's disease (AD), i.e., advanced age, apolipoprotein E (ApoE) ε4, and female gender, are associated with differential levels of ApoE proteins and butyrylcholinesterase (BuChE) in the cerebrospinal fluid (CSF) of AD patients. The ApoE ε4 allele and certain BuChE polymorphisms synergistically affect the conversion rate of mild cognitive impairment (MCI) to AD. Here, we investigated interrelationships between ApoE and BuChE levels, and pathological markers of AD in vivo. CSF from patients with probable AD, assessed for cerebral glucose metabolism (CMRglc; n = 50) and Pittsburgh compound B (PIB) retention (β-amyloid [Aβ] load, n = 29) by positron emission tomography (PET), was used for measurement of BuChE, ApoE, Aβ, tau, phosphorylated tau (P-tau) and interleukin-1β (IL-1β) levels. Levels of ApoE and BuChE strongly correlated with CMRglc (fluorodeoxyglucose [FDG]-PET, r = 0.54, p &lt; 0.0001, n = 50), cerebral Aβ load (PIB retention, r = 0.73, p &lt; 0.0001, n = 29), and CSF P-tau ( r = 0.73, p &lt; 0.0001, n = 33). High ApoE protein was tied to low CMRglc and high PIB retention and P-tau. BuChE levels had opposite relationships. Other CSF covariates were levels of interleukin-1β and Aβ42 peptide. The pattern of the patients' cognitive Z -scores strongly supported these observations. High ApoE protein was also linked to changes in 3 of the biodynamic properties of BuChE. In vitro analysis indicated that high ApoE protein levels were related to an increased pool of dormant BuChE molecules with an abnormally high intrinsic catalytic rate in CSF, which was “turned on” by excess Aβ peptides. The findings suggest that abnormally high levels of ApoE may play a causative role in the pathological events of AD, particularly those involving the early cholinergic deficit in the AD brain, through modulation of cholinesterases activities, hence disturbing the acetylcholine-dependent activity of neurons and nonexcitable cells such as glial cells.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20538374</pmid><doi>10.1016/j.neurobiolaging.2010.04.028</doi></addata></record>
fulltext fulltext
identifier ISSN: 0197-4580
ispartof Neurobiology of aging, 2011-12, Vol.32 (12), p.2320.e15-2320.e32
issn 0197-4580
1558-1497
1558-1497
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_550841
source MEDLINE; Elsevier ScienceDirect Journals
subjects Aged
Alzheimer Disease - cerebrospinal fluid
Alzheimer Disease - enzymology
Alzheimer Disease - pathology
Alzheimer’s disease
apolipoprotein E
Apolipoprotein E4 - blood
Apolipoprotein E4 - cerebrospinal fluid
Biomarkers - blood
Biomarkers - cerebrospinal fluid
brain
Brain - enzymology
Brain - pathology
butyrylcholinesterase
Butyrylcholinesterase - cerebrospinal fluid
Female
Humans
Internal Medicine
Male
Middle Aged
Neurology
Psychiatry
Psychology
Psykiatri
Psykologi
Risk Factors
SAMHÄLLSVETENSKAP
SOCIAL SCIENCES
Socialvetenskap
title Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A15%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20levels%20of%20apolipoprotein%20E%20and%20butyrylcholinesterase%20show%20strong%20association%20with%20pathological%20signs%20of%20Alzheimer's%20disease%20in%20the%20brain%20in%20vivo&rft.jtitle=Neurobiology%20of%20aging&rft.au=Darreh-Shori,%20Taher&rft.date=2011-12-01&rft.volume=32&rft.issue=12&rft.spage=2320.e15&rft.epage=2320.e32&rft.pages=2320.e15-2320.e32&rft.issn=0197-4580&rft.eissn=1558-1497&rft_id=info:doi/10.1016/j.neurobiolaging.2010.04.028&rft_dat=%3Cproquest_swepu%3E911157939%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=898191002&rft_id=info:pmid/20538374&rft_els_id=S0197458010002034&rfr_iscdi=true